Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment engages in the development, production and marketing of prescription products for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology and ophthalmology; diagnostic imaging equipment and the necessary contrast agents. The Consumer Health segment manufactures and markets products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories. The CropScience segment includes seeds and plant traits, crop protection and nonagricultural pest control. The Animal Health segment offers prescription and nonprescription veterinary products. The Covestro segment provides raw materials for polyurethanes; polycarbonate granules and sheets; raw materials for coatings, adhesives and sealants; and by-products of polyether production and of chlorine production and use. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA.

Fujian Yongjing Technology Co. Ltd. is a private company headquartered in Shaowu City, China. The firm engages in research & development, production and sales of fluorine fine products. It was founded in 2007. Jia Long Du is the current CEO of the firm.

Taiho Pharmaceutical Co., Ltd. is engaged in the research, development, production, distribution, and marketing of pharmaceutical products. The company develops drugs primarily in the area of oncology. It also develops other pharmaceuticals, controlled medical devices, designated quasi-drugs, second-class OTC drugs, designated second-class OTC drugs, and third-class OTC drugs; S-1 for the treatment of gastric cancer; TAS-102 for the treatment of colorectal cancer; and anticancer agents for oncologists, other medical care professionals, and patients. In addition, it engages in the research and development in the areas of oncology,

Merck (d.b.a. EMD Millipore in the U.S. and Canada) is a German chemical and pharmaceutical company. Merck, also known as “German Merck” and “Merck Darmstadt”, was founded in Darmstadt, Germany, in 1668, making it the world's oldest operating chemical and pharmaceutical company. The company was privately owned until going public in 1995. However, the Merck family still controls a majority (≈70%) of the company's shares. Following World War I, Merck lost possession of its foreign sites, including the Merck & Co. subsidiary in the United States. Merck & Co., which operates as Merck Sharp and Dohme (MSD) outside the U.S. and Canada, is now an independent company. Merck KGaA operates mainly in Europe, Africa, Asia, Oceania and Latin America. Since Merck & Co. holds the rights to the Merck name in the U.S. and Canada, the company operated under the umbrella brand EMD Chemicals in North America, and since 2010 as EMD Millipore (after the acquisition of Millipore Corporation), formed from the initials of Emanuel Merck, Darmstadt. Founded in 1668 in Darmstadt, Merck KGaA of Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The success of the export business to the United States led in 1887 to the establishment of an office in New York, which gave rise to their subsidiary [Merck & Co.](http://www.crunchbase.com/organization/merck-co-inc) four years later. Owing to World War I, Merck & Co. was expropriated in 1917. The two companies have been separate every since. Merck KGaA Subsidiaries: - [Merck Consumer Healthcare](http://www.crunchbase.com/organization/merck-consumer-healthcare) - [Merck Performance Materials](http://www.crunchbase.com/organization/merck-performance-materials)

Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium and owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen. In 1961, Janssen Pharmaceutica was purchased by New Jersey-based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company.

Xiangshui New United Chemical Co., Ltd. is located in Chenjiagang Town, a hundred famous towns in Jiangsu Province. Chenjia Port is adjacent to 326 Provincial Highway and 228 Coastal Expressway in the east, G15 Expressway and 204 National Highway in the west. The port is not frozen all the year round. It is 374 nautical miles away from Shanghai Port in the south and 29 nautical miles away from Lianyungang in the north. There is one 10000 ton wharf, two 3000 ton wharves, and more than 10 1000 ton wharves. The annual throughput is more than 5 million tons. Guanhe River, known as the "Huangpu River in Northern Jiangsu", connects with the Beijing Hangzhou Grand Canal and Tongyu River in the Yellow Sea in the east, and can be connected with domestic port cities and coastal countries With direct navigation, developed transportation and beautiful scenery, the region is known as the "Pearl of the Yellow Sea". Our company is a key enterprise in the fluoride fine chemical industry. Existing fluorobenzene, o-fluorotoluene, m-fluorotoluene, p-fluorotoluene, hydrofluoric acid and other products. The company has strong technical force, complete product testing means and quality assurance system. The company pays close attention to the scientific research and production trends at home and abroad, establishes cooperation with domestic scientific research institutions and universities, and constantly develops and researches new products according to the market and user feedback information to meet the different needs of customers. The company has always adhered to the business purpose of "quality first, customer first", and advocated the enterprise philosophy of "people-oriented, pragmatic and innovative". Constantly strengthen the construction of corporate culture, improve their own competitiveness, and strive to improve product quality and service quality, so that the company will become an advanced enterprise in the chemical industry. We look forward to working with friends from all walks of life to create a new future!

Atopix Therapeutics Limited is a privately held, clinical-stage, biopharmaceutical company based in Oxford, UK, with an innovative approach to allergy. The company is developing a novel class of oral anti-allergic medicines, called CRTH2 antagonists, to treat atopic dermatitis, asthma and allergic rhinitis. Its lead candidate is currently being studied in a Phase 2 clinical trial for moderate to severe atopic dermatitis in several leading European dermatology centres.

AGC, Inc. engages in the manufacture and sale of glass, electronic materials, and chemicals. It operates through the following segments: Glass, Electronics, Chemicals, Ceramics and Other. The Glass segment provides security glass, fire-resistant glass, heat insulating glass, and automotive glass. The Electronics segment offers glass for display panels, optical thin film products, opto-electronic materials, synthetic quartz products, semiconductor components, and lighting products. The Chemicals segment deals with chlor-alkali and urethane products, water and oil repellents, solvents, gases, and specialty chemicals. The Ceramics and Other segment includes ceramic products, logistics, and financial services. The company was founded by Toshiya Iwasaki on September 8, 1907 and is headquartered in Tokyo, Japan.

Bayer Schering Pharma AG is a research-centered pharmaceutical company that was formed by the merger of Schering with Bayer on 29 December 2006. The company was originally founded in 1851 by Ernst Christian Friedrich Schering. The company employs more than 26,000 people in 140 subsidiaries all over the world. The company's headquarters are in Berlin-Wedding, Germany and the forerunner company Schering's annual gross revenue was nearly € 5 billion. They retain the largest German manufacturing facility which is located in Bergkamen. The company focuses on the business areas of gynaecology and andrology, oncology, and also special therapeutics, diagnostical devices, and nuclear medicine. Schering's best-known product is their line of combined oral contraceptive pills. Through Bayer Healthcare AG, Bayer Schering Pharma is a full member of the European Federation of Pharmaceutical Industries and Associations.

Brewer Science, Inc. develops and manufactures innovative materials, processes and equipment for the fabrication of semiconductors and microelectronic devices. The firm's solutions include ARC anti reflective coatings, ProTEK materials, WaferBOND system, specialty materials and carbon nanotube coating. The company was founded by Terry Brewer in 1981 and is headquartered in Rolla, MO.

Bayer HealthCare Ltd., established on 1995-08-25, Business scope includes licensed projects:pharmaceutical production;Pharmaceutical commissioned production;Drug Wholesale;Drug import and export;Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;food sales;Health food production;food production;Production of formula food for special medical purpose;Cosmetic production;Production of hygiene products and single-use medical products;Disinfectant production(Free of Hazardous Chemicals).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Cosmetics Wholesale;Cosmetics Retail;internet sales(Except for products that require a license for sale);Food import and export;software development;software sales;Retailing of computer software, hardware and auxiliary equipment;Wholesale of computer software, hardware and auxiliary equipment;Manufacturing of computer software, hardware and peripheral equipment;Software outsourcing service;Information Consulting Service(Not including licensing information consulting services);Information Technology Consulting Services;Special Equipment Repair;Import and export;Technology Import and Export;Import and export agency;Sales of hygiene products and single-use medical products;Disinfectant sales(Free of Hazardous Chemicals);Manufacturing of daily chemical products;Sales of daily chemical products.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)(Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Develops and manufactures agricultural and noncrop products

Zhejiang Huahai Pharmaceutical Co. Ltd. engages in the manufacture and sale of pharmaceutical products. It also integrates and intermediates formulations such as Active Pharmaceutical Ingredients. Its products include Irbesartan and Hydrochlorothiazide Tablet, Paroxetine Hydrochloride Tablet and Irbesartan Tablet. The company was founded in 1989 and is headquartered in Zhejiang, China.

Shanghai Kesheng Pharmaceutical Research and Development Co., Ltd., established on 2005-04-08, Business scope includes biological,Research and development of pharmaceutical products and technology transfer,Sales of pharmaceutical intermediates,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Dexing Debang Chemical Co., Ltd., established on 2006-05-10, Business scope includes licensed projects:Hazardous Chemical Production,Hazardous Chemicals Management(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals),Specialty Chemicals Sales(Free of Hazardous Chemicals),Manufacturing of basic chemical raw materials(Manufacture of licensed chemicals free of hazardous chemicals),Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion,New material technology research and development(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Shandong Fuer Co., Ltd. manufactures and distributes chemical products. Its products include pesticides, medicine intermediate, and dye intermediate. The company was founded on April 28, 1994 and is headquartered in Longkou, China.

Shanghai Chemspec Corp. engages in the research, development, production, and sale of fine chemicals. Its products are display materials, new energy battery materials, electronic chemicals, organic silicon materials, as well as pharmaceutical and agrochemical chemicals. The company was founded by Jian Hua Yang on November 14, 1996 and is headquartered in Shanghai, China.

DIC Corp. engages in the manufacture and sale of printing inks, organic pigments, and synthetic resins. It operates through the following segments: Packaging and Graphic, Color and Display, Functional Products, and Others. The Packaging and Graphic segment sells gravure, flexographic, security, offset and news inks, packaging adhesives, polystyrene, and coextruded multilayer films. The Color and Display segment includes products such as organic pigments, health food, natural colorants, and thin-film-transistor liquid-crystal display (TFT LCD). The Functional Products segment offers water-based, acrylic, epoxy, polyester and phenolic resins, Sulphur chemicals, magnetic tapes, and molded plastic products. The Others segment handles other products not mentioned in the above segments. The company was founded on February 15, 1908 and is headquartered in Tokyo, Japan.